Author + information
- Received August 14, 2017
- Revision received December 8, 2017
- Accepted December 11, 2017
- Published online March 5, 2018.
- Carlos D. Davila, MD and
- James E. Udelson, MD∗ ()
- ↵∗Address for correspondence:
Dr. James E. Udelson, Division of Cardiology, Tufts Medical Center, 800 Washington Street, Boston, Massachusetts 02111.
Among all patients referred for stress myocardial perfusion imaging (MPI), a substantial proportion in contemporary practice cannot exercise. Another group of patients are those who are thought to be able to achieve an adequate workload with treadmill (or bicycle) exercise but do not achieve at least 85% of maximum predicted heart rate without developing symptoms. There has been substantial interest and literature on the adjunctive use of vasodilator stress during the same visit to generate best-quality results for patients who do not exercise adequately. Current American Society of Nuclear Cardiology Guidelines recommend the possible use of vasodilator stress agents to supplement exercise in those patients who do not achieve target heart rate. However, optimal timing of administration is not clear. Herein, we summarize literature to date on the combination of vasodilator and exercise stress testing in light of the recently published Exercise to Regadenoson in Recovery Trial (EXERRT).
Dr. Udelson is a consultant to Lantheus Medical Imaging, GE Healthcare, and Medtrace for imaging studies, but none of these is considered relevant to the topic at hand. Dr. Davila has reported that he has no relationships relevant to the contents of this paper to disclose.
- Received August 14, 2017.
- Revision received December 8, 2017.
- Accepted December 11, 2017.
- 2018 American College of Cardiology Foundation
This article requires a subscription or purchase to view the full text. If you are a subscriber or member, click Login or the Subscribe link (top menu above) to access this article.